Convert Pharmaceuticals is a startup based in Belgium, most recent round Series A.
Based in Belgium, Convert Pharmaceuticals is a startup. Its most recent tracked round is Series A.
Convert Pharmaceuticals develops tumor microenvironment-activated prodrugs that remain inactive until reaching hypoxic tumor sites, aiming to improve cancer treatment effectiveness and tolerability.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.